Amgen Inc (AMGN) - Total Liabilities
Based on the latest financial reports, Amgen Inc (AMGN) has total liabilities worth $81.93 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amgen Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Amgen Inc's total liabilities have evolved over time, based on quarterly financial data. See Amgen Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Amgen Inc Competitors by Total Liabilities
The table below lists competitors of Amgen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verizon Communications Inc
NYSE:VZ
|
USA | $313.26 Billion |
|
SHELL PLC WI ADR/2
F:L3H
|
Germany | €195.03 Billion |
|
LOréal S.A.
PA:OR
|
France | €26.82 Billion |
|
Seagate Technology PLC
NASDAQ:STX
|
USA | $7.80 Billion |
|
Siemens Aktiengesellschaft
XETRA:SIE
|
Germany | €104.65 Billion |
|
Toyota Motor Corporation
F:TOM
|
Germany | €62.35 Trillion |
|
IND.D.D.TEXT.UNSP.ADR 1/2
F:IXD2
|
Germany | €18.04 Billion |
|
Western Digital Corporation
NASDAQ:WDC
|
USA | $5.37 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Amgen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Amgen Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amgen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amgen Inc (1985–2025)
The table below shows the annual total liabilities of Amgen Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $81.93 Billion | -4.69% |
| 2024-12-31 | $85.96 Billion | -5.46% |
| 2023-12-31 | $90.92 Billion | +47.94% |
| 2022-12-31 | $61.46 Billion | +12.84% |
| 2021-12-31 | $54.47 Billion | +1.73% |
| 2020-12-31 | $53.54 Billion | +7.01% |
| 2019-12-31 | $50.03 Billion | -7.20% |
| 2018-12-31 | $53.92 Billion | -1.46% |
| 2017-12-31 | $54.71 Billion | +14.58% |
| 2016-12-31 | $47.75 Billion | +10.11% |
| 2015-12-31 | $43.37 Billion | +0.31% |
| 2014-12-31 | $43.23 Billion | -1.81% |
| 2013-12-31 | $44.03 Billion | +24.95% |
| 2012-12-31 | $35.24 Billion | +18.08% |
| 2011-12-31 | $29.84 Billion | +52.71% |
| 2010-12-31 | $19.54 Billion | +15.21% |
| 2009-12-31 | $16.96 Billion | +5.64% |
| 2008-12-31 | $16.06 Billion | -4.25% |
| 2007-12-31 | $16.77 Billion | +13.13% |
| 2006-12-31 | $14.82 Billion | +67.58% |
| 2005-12-31 | $8.85 Billion | -7.04% |
| 2004-12-31 | $9.52 Billion | +41.52% |
| 2003-12-31 | $6.72 Billion | +8.98% |
| 2002-12-31 | $6.17 Billion | +403.30% |
| 2001-12-31 | $1.23 Billion | +12.98% |
| 2000-12-31 | $1.09 Billion | +2.94% |
| 1999-12-31 | $1.05 Billion | -5.04% |
| 1998-12-31 | $1.11 Billion | +14.33% |
| 1997-12-31 | $970.90 Million | +12.99% |
| 1996-12-31 | $859.30 Million | +12.92% |
| 1995-12-31 | $761.00 Million | +5.72% |
| 1994-12-31 | $719.80 Million | +21.28% |
| 1993-12-31 | $593.50 Million | +34.70% |
| 1992-12-31 | $440.60 Million | +31.76% |
| 1991-12-31 | $334.40 Million | +188.28% |
| 1990-12-31 | $116.00 Million | -3.33% |
| 1989-12-31 | $120.00 Million | +165.49% |
| 1988-12-31 | $45.20 Million | +54.27% |
| 1987-12-31 | $29.30 Million | +128.91% |
| 1986-12-31 | $12.80 Million | -2.29% |
| 1985-12-31 | $13.10 Million | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more